$IRTC

Shrishrimal Sumi sold $186K of IRTC

Shrishrimal Sumi (EVP, Chief Risk Officer) sold 1,716 shares of iRhythm Holdings, Inc. (IRTC) at $108.19 ($0.19M total) on 2026-06-02.

Original reporting
SEC EDGAR · Shrishrimal Sumi
Published Jun 3, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IRTC
Neutral
medium confidence
Mentioned
$IRTC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRTCNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity or other catalysts, but the filing alone typically does not change valuation drivers.

02

Market read

Near-term sentiment could be slightly negative/uncertain due to disclosed insider selling, but no fundamental new information is provided.

03

What to watch

The article lacks context on total insider holdings, prior sale frequency, and whether other insiders simultaneously bought/sold, limiting inference.

Relevance 6/10Novelty 6/10Timing: Filed June 3; sale executed June 2 (post-transaction disclosure).

Background

This is an SEC Form 4 insider transaction disclosure (open-market sale) by an IRTC executive; it does not include performance or business updates.

Company-level read

Ticker impact

$IRTCNeutralMedium confidence
Context

SEC Form 4 shows IRTC Chief Risk Officer Shrishrimal Sumi sold 1,716 shares in an open-market transaction for ~$185.7K.

Expected impact

Likely limited/short-lived impact; any move would be sentiment-driven rather than driven by new fundamentals.

Evidence & confidence

The filing provides a single officer sale datapoint (size disclosed) with no stated reason, and insider sales are often non-informational absent corroborating news.

Market effects

Minimal; this is company-specific insider activity with no sector-wide regulatory/product implication stated.

None indicated.

None indicated.

Counterpoint

Officer sales can reflect diversification or routine liquidity needs; without a 10b5-1 plan, it still may not signal negative fundamentals.

Key entities

  • iRhythm Holdings, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Shrishrimal Sumi

    EVP, Chief Risk Officer who sold 1,716 shares of IRTC.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RMDMedAI 8/10

Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest

ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.

$IRTCMedAI 9/10

iRhythm (IRTC) Q2 2026 Earnings Call Transcript

iRhythm (IRTC) reported Q2 2026 revenue of $224.2M, up 20.1% YoY, with gross margin at 72.8%. GAAP net loss was $0.4M, and adjusted EBITDA was $43.3M. Full-year revenue guidance is $880M to $890M and adjusted EBITDA margin 13% to 14%. The company agreed to acquire VitalConnect for about $287.5M and received a $50M Baxter settlement.